Notify me when Blue Water Life Science Advisors, LP files a new 13F portfolio report.
⭐ Subscribe ⭐| Quarter | Holdings | Value $ | Bought | Sold | Net | Top Holdings | Form Type | Filing Time |
|---|---|---|---|---|---|---|---|---|
| Q4 2025 | 9 | $159,327,918 | +$28,663,654 | -$11,339,484 | +$17,324,170 | GH, NTRA, ADPT, PSNL, QTRX | 13F-HR | 17 Feb 2026, 12:17 |
| Q3 2025 | 7 | $109,602,298 | +$5,844,373 | -$28,076,305 | -$22,231,932 | ADPT, GH, NTRA, PSNL, CDNA | 13F-HR | 14 Nov 2025, 10:19 |
| Q2 2025 | 8 | $126,332,680 | +$19,926,296 | -$20,365,680 | -$439,384 | NTRA, ADPT, GH, CDNA, TXG | 13F-HR | 14 Aug 2025, 09:53 |
| Q1 2025 | 7 | $100,917,649 | +$4,191,945 | -$14,015,871 | -$9,823,926 | GH, NTRA, ADPT, CDNA, AKYA | 13F-HR | 15 May 2025, 10:01 |
| Q4 2024 | 9 | $112,936,806 | +$11,230,212 | -$15,658,206 | -$4,427,994 | NTRA, GH, CDNA, ADPT, AKYA | 13F-HR | 13 Feb 2025, 15:38 |
| Q3 2024 | 8 | $113,705,544 | +$32,779,240 | -$39,099,132 | -$6,319,892 | NTRA, CDNA, EXAS, AKYA, ADPT | 13F-HR | 14 Nov 2024, 15:16 |
| Q2 2024 | 8 | $102,826,250 | +$8,610,775 | -$5,822,952 | +$2,787,823 | NTRA, GH, AKYA, CDNA, TXG | 13F-HR | 09 Aug 2024, 12:57 |
| Q1 2024 | 8 | $106,316,114 | +$14,115,922 | -$20,373,151 | -$6,257,229 | NTRA, AKYA, GH, TXG, QTRX | 13F-HR | 15 May 2024, 16:37 |
| Q4 2023 | 9 | $114,165,458 | +$32,457,881 | -$36,237,143 | -$3,779,262 | NTRA, AKYA, GH, TMO, TXG | 13F-HR | 14 Feb 2024, 16:24 |
| Q3 2023 | 7 | $105,925,096 | +$1,763,000 | -$7,274,591 | -$5,511,591 | NTRA, AKYA, GH, ADPT, NSTGQ | 13F-HR | 14 Nov 2023, 16:34 |
| Q2 2023 | 7 | $148,155,168 | +$36,902,461 | -$27,781,994 | +$9,120,467 | NTRA, AKYA, GH, ADPT, NSTGQ | 13F-HR | 14 Aug 2023, 16:34 |
| Q1 2023 | 8 | $151,234,037 | +$13,484,684 | -$15,592,235 | -$2,107,551 | NTRA, ADPT, AKYA, MXCT, GH | 13F-HR | 15 May 2023, 16:20 |
| Q4 2022 | 8 | $148,863,925 | +$18,117,619 | -$71,389,025 | -$53,271,406 | NTRA, GH, ADPT, AKYA, MXCT | 13F-HR | 14 Feb 2023, 09:14 |
| Q3 2022 | 9 | $247,765,000 | +$68,184,843 | -$22,111,000 | +$46,073,843 | GH, NTRA, CTKB, TWST, ADPT | 13F-HR | 14 Nov 2022, 15:45 |
| Q2 2022 | 9 | $184,130,000 | +$87,261,733 | -$75,325,415 | +$11,936,318 | GH, NTRA, AKYA, ADPT, CTKB | 13F-HR | 15 Aug 2022, 12:36 |
| Q1 2022 | 10 | $210,714,000 | +$94,212,741 | -$135,476,000 | -$41,263,259 | NTRA, GH, CDNA, PACB, AKYA | 13F-HR | 18 May 2022, 15:22 |
| Q4 2021 | 13 | $326,892,000 | +$97,663,286 | -$53,994,674 | +$43,668,612 | NTRA, TMO, GH, CDNA, TECH | 13F-HR | 14 Feb 2022, 15:49 |
| Q3 2021 | 24 | $306,758,000 | +$139,032,830 | -$88,940,256 | +$50,092,574 | NTRA, CDNA, TMO, TECH, A | 13F-HR | 15 Nov 2021, 16:18 |
| Q2 2021 | 22 | $265,139,000 | +$94,353,768 | -$43,032,000 | +$51,321,768 | NTRA, CDNA, AMRSQ, TMO, NEO | 13F-HR | 13 Aug 2021, 12:03 |
| Q1 2021 | 24 | $204,307,000 | +$35,185,678 | -$18,829,595 | +$16,356,083 | AMRSQ, CDNA, NTRA, GH, EXAS | 13F-HR | 14 May 2021, 13:56 |
| Q4 2020 | 21 | $170,376,000 | $0 | $0 | $0 | CDNA, NTRA, GH, CELL, AMRSQ | New Holdings | 14 May 2021, 13:59 |
| Q4 2020 | 11 | $165,150,000 | $0 | $0 | $0 | CDNA, NTRA, GH, CELL, AMRSQ | 13F-HR | 16 Feb 2021, 06:11 |